# A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

Study · id `cardio:ct-nct02698839` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02698839](<https://clinicaltrials.gov/study/NCT02698839>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02698839

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 539 participants.

## Technical summary

Registry record NCT02698839. Randomized; single masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 539 participants (planned count; ClinicalTrials.gov record NCT02698839, source copy `cardio:ctgov-nct02698839-2024-04-25`, retrieved 2026-10-26)
- Started: 2015-12 (actual) (ClinicalTrials.gov record NCT02698839, source copy `cardio:ctgov-nct02698839-2024-04-25`, retrieved 2026-10-26)
- Primary completion: 2018-03 (actual) (ClinicalTrials.gov record NCT02698839, source copy `cardio:ctgov-nct02698839-2024-04-25`, retrieved 2026-10-26)
- Completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT02698839, source copy `cardio:ctgov-nct02698839-2024-04-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02698839, source copy `cardio:ctgov-nct02698839-2024-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02698839-2024-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
- Acronym: RCT
- Condition: Coronary Artery Disease
- Intervention (Device): BuMA Supreme
- Intervention (Device): BuMA™
- Lead sponsor: Sino Medical Sciences Technology Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Sino Medical Sciences Technology Inc. (`cardio:org-sino-medical-sciences-technology-inc`)

## Provenance

Content hash: 836d9b8e0eb021235d49e3a5cc6540bd2e5f126a4e0eb8b8e2f6d5222e278462
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
